IDENTIFY THE ONCOGENIC SIGNALING DEPENDENCIES THAT CHARACTERIZE EACH OF THE CELLULAR SUBPOPULATIONS THAT COMPRISE A GLIOBLASTOMA TUMOR, AND FROM THIS INFORMATION CONSTRUCT A NON-TOXIC COMBINATION OF KINASE INHIBITORS TO EFFECTIVELY TREAT THIS DISEASE.

PIs: Steven Rosenfeld, M.D., Ph.D.
Professor, Departments of Oncology, Neurology, and Molecular Pharmacology
Deputy Director
Mayo Clinic Comprehensive Cancer Center

PIs: Peter D. Canoll, M.D., Ph.D.
Director of Neuropathology
Professor of Pathology and Cell Biology
Columbia University, Department of Pathology and Cell Biology

Close Menu